Does NILOTINIB Cause Second primary malignancy? 337 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 337 reports of Second primary malignancy have been filed in association with NILOTINIB (nilotinib). This represents 1.5% of all adverse event reports for NILOTINIB.
337
Reports of Second primary malignancy with NILOTINIB
1.5%
of all NILOTINIB reports
60
Deaths
100
Hospitalizations
How Dangerous Is Second primary malignancy From NILOTINIB?
Of the 337 reports, 60 (17.8%) resulted in death, 100 (29.7%) required hospitalization, and 13 (3.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NILOTINIB. However, 337 reports have been filed with the FAERS database.
What Other Side Effects Does NILOTINIB Cause?
Death (2,667)
Fatigue (1,679)
Rash (1,250)
Nausea (1,180)
Headache (1,177)
Pain (1,169)
Dyspnoea (1,070)
Diarrhoea (998)
Drug ineffective (992)
Malaise (961)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which NILOTINIB Alternatives Have Lower Second primary malignancy Risk?
NILOTINIB vs NIMESULIDE
NILOTINIB vs NIMODIPINE
NILOTINIB vs NINTEDANIB
NILOTINIB vs NINTEDANIB ESYLATE
NILOTINIB vs NIRAPARIB